Vigil Neuroscience Inc (VIGL) - Total Liabilities
Based on the latest financial reports, Vigil Neuroscience Inc (VIGL) has total liabilities worth $45.44 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vigil Neuroscience Inc - Total Liabilities Trend (2020–2024)
This chart illustrates how Vigil Neuroscience Inc's total liabilities have evolved over time, based on quarterly financial data. See Vigil Neuroscience Inc (VIGL) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Vigil Neuroscience Inc Competitors by Total Liabilities
The table below lists competitors of Vigil Neuroscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wei Long Grape Wine Co Ltd
SHG:603779
|
China | CN¥463.06 Million |
|
Benchmark Metals Inc
V:CEI
|
Canada | CA$114.34 Million |
|
Ace Hardware Indonesia Tbk
JK:ACES
|
Indonesia | Rp2.28 Trillion |
|
Shenzhen Crastal Technology Co Ltd
SHE:300824
|
China | CN¥289.79 Million |
|
Plaza Retail REIT
TO:PLZ-UN
|
Canada | CA$712.84 Million |
|
Jiangmen Kanhoo Industry Co Ltd
SHE:300340
|
China | CN¥2.41 Billion |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
USA | $29.40 Million |
|
Shanthi Gears Limited
NSE:SHANTIGEAR
|
India | Rs1.16 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Vigil Neuroscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VIGL stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vigil Neuroscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vigil Neuroscience Inc (2020–2024)
The table below shows the annual total liabilities of Vigil Neuroscience Inc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $46.06 Million | +87.17% |
| 2023-12-31 | $24.61 Million | +117.52% |
| 2022-12-31 | $11.31 Million | -93.42% |
| 2021-12-31 | $171.88 Million | +220.80% |
| 2020-12-31 | $53.58 Million | -- |
About Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more